中国公司开发来自大米的人类血蛋白,目标是在2026年取代25%的进口。 Chinese company develops human blood protein from rice, aiming to replace 25% of imports by 2026.

中国一家名为 " 健康生物技术 " 的公司开发了一种利用基因工程从稻米中生产人类血清蛋白(HSA)的方法,这是一种关键的血液产品。 A Chinese company, Healthgen Biotechnology, has developed a method to produce human serum albumin (HSA), a critical blood product, from rice using genetic engineering. 这一突破有助于解决中国HSA短缺的问题,其生产量相当于5升等离子体中25公斤大米的产量。 This breakthrough helps address China's shortage of HSA by producing an equivalent amount from 25 kg of rice as found in five liters of plasma. 目前,该公司每年生产10吨,预计到2026年将达到130吨,取代进口的25%。 Currently producing 10 tonnes annually, the company expects to reach 130 tonnes by 2026, replacing about 25% of imports. 该产品已经完成了第三阶段临床试验,预计将于2025年6月获得批准。 The product has completed Phase III clinical trials and is expected to be approved in June 2025.